MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 139 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $222,000 | -27.0% | 3,100 | 0.0% | 0.06% | -22.8% |
| Q1 2022 | $304,000 | -36.0% | 3,100 | -44.6% | 0.08% | -33.6% |
| Q4 2021 | $475,000 | +6.3% | 5,600 | 0.0% | 0.12% | 0.0% |
| Q3 2021 | $447,000 | -18.0% | 5,600 | 0.0% | 0.12% | +4.4% |
| Q2 2021 | $545,000 | -16.8% | 5,600 | 0.0% | 0.11% | -26.5% |
| Q1 2021 | $655,000 | -10.8% | 5,600 | -15.2% | 0.16% | -28.9% |
| Q4 2020 | $734,000 | -6.4% | 6,600 | 0.0% | 0.22% | -14.5% |
| Q3 2020 | $784,000 | +5.0% | 6,600 | 0.0% | 0.26% | +18.1% |
| Q2 2020 | $747,000 | -17.7% | 6,600 | -51.5% | 0.22% | -43.0% |
| Q1 2020 | $908,000 | -26.7% | 13,600 | 0.0% | 0.38% | -10.8% |
| Q4 2019 | $1,239,000 | +117.8% | 13,600 | +106.1% | 0.42% | +98.6% |
| Q3 2019 | $569,000 | -17.8% | 6,600 | 0.0% | 0.21% | -17.7% |
| Q2 2019 | $692,000 | -16.3% | 6,600 | 0.0% | 0.26% | -27.2% |
| Q1 2019 | $827,000 | +11.2% | 6,600 | 0.0% | 0.36% | -3.5% |
| Q4 2018 | $744,000 | – | 6,600 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paulson & Co. | 1,850,000 | $518,296,000 | 38.31% |
| Tao Capital Management LP | 130,529 | $36,569,005 | 29.98% |
| University of Wisconsin Foundation | 45,730 | $12,811,717 | 14.42% |
| AlpInvest Partners B.V. | 84,595 | $23,700,135 | 8.50% |
| RTW INVESTMENTS, LP | 1,915,862 | $536,747,898 | 8.31% |
| Propel Bio Management, LLC | 43,032 | $12,055,845 | 7.82% |
| Avoro Capital Advisors LLC | 2,055,555 | $575,884,289 | 7.67% |
| Baker Brothers Advisors | 1,974,590 | $553,201,134 | 7.07% |
| Tri Locum Partners LP | 65,352 | $18,309,016 | 4.63% |
| TCG Crossover Management, LLC | 149,283 | $41,823,125 | 4.36% |